title: Indobufen vs acetylsalicylic acid plus dipyridamole in long-term patency after femoropopliteal bypass.
abstract: To compare the effects of indobufen (INB) with those of ASA+dipyridamole (DP) on graft patency, 113 patients undergoing femoropopliteal bypass surgery were randomly and blindly assigned to treatment with INB 400 mg daily or with ASA 900 mg daily plus DP 225 mg daily. Treatment started 2 days before surgery and lasted for 12 months. All patients underwent two angiographic examinations: the first early after surgery (mean 6 days) and the second at the end of the study (mean 368 days). The 1 year cumulative patency rate for INB was 60% higher but not statistically different from the ASA-DP group (53.2%). The relative risk (INB/ASA+DP) calculated by the Mantel-Haenszel test was 0.86 (confidence limits 0.54-1.35). Only the site of operation (above-knee or below-knee) has a significant prognostic value on the fate of the graft.
authors.affiliation: Cattedra di Chirurgia Vascolare, Policlinico S. Orsola, Bologna, Italy.
authors.forename: M
authors.initials: M
authors.lastname: D'Addato
authors.forename: T
authors.initials: T
authors.lastname: Curti
authors.forename: D
authors.initials: D
authors.lastname: Bertini
authors.forename: I
authors.initials: I
authors.lastname: Donini
authors.forename: R
authors.initials: R
authors.lastname: Ferrero
authors.forename: P
authors.initials: P
authors.lastname: Fiorani
authors.forename: F
authors.initials: F
authors.lastname: Pellegrino
authors.forename: R
authors.initials: R
authors.lastname: Vecchioni
authors.forename: W
authors.initials: W
authors.lastname: Visconti
authors.forename: N
authors.initials: N
authors.lastname: Zinicola
mesh_terms: D000368:Aged; D001157:Arterial Occlusive Diseases / Q000000981:diagnostic imaging / Q000401:mortality / Q000601:surgery*; D001166:Arteriovenous Shunt, Surgical / Q000009:adverse effects; D001241:Aspirin / Q000627:therapeutic use*; D004176:Dipyridamole / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D005263:Femoral Artery / Q000000981:diagnostic imaging / Q000601:surgery*; D006801:Humans; D054833:Isoindoles; D008297:Male; D010349:Patient Compliance; D010654:Phenylbutyrates / Q000627:therapeutic use*; D010975:Platelet Aggregation Inhibitors / Q000627:therapeutic use*; D011152:Popliteal Vein / Q000000981:diagnostic imaging / Q000601:surgery*; D011859:Radiography; D015996:Survival Rate; D014654:Vascular Patency / Q000187:drug effects*
chemical_list: D054833:Isoindoles; D010654:Phenylbutyrates; D010975:Platelet Aggregation Inhibitors; D004176:Dipyridamole; C020371:indobufen; D001241:Aspirin